CYBN:CC News and Press, CYBIN INC. From 06/16/22

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat and panel discussion at the H.C. Wainwright 1st Annual Mental Health ...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ” is pleased to announce that Doug Drysdale, Cybin’s Chie...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage biopharmaceutical company committed to progressing Psychedelics to Therapeutics(TM), has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. “T...

Everyone has experienced it at least once in their lives: you walk into a room with purpose only to realize you have no idea what you came for. You stare at the room, racking your brain for information, but all you draw is a blank. This state of temporary amnesia is the concept behind ego ...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a number of mental health conditions. The Tesla CEO said ...

Runaway climate change isn’t only about ravaging the planet and making it unlivable for humans, it is also actively about impacting mental health around the world. According to a new policy brief from the World Health Organization (WHO), climate change presents a significant risk to...

A couple weeks ago, a psychedelic conference known as the Catalyst Summit was held in Ontario. Representatives of Health Canada, politicians, researchers and leaders of psychedelic drug companies as well as trained therapists and patients who had gained benefit from psychedelic drugs gathe...

Cybin (NEO: CYBN) (NYSE American: CYBN) , a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluatin...

-- F irst-in-human Phase 1/2a trial evaluating the proprietary deuterated psilocybin analog CYB003 expected to begin in mid-2022 -- Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) ( Cybin or the “ Company” ), a biopharmaceutical company focused...

A new study that looked into the relationship between an individual’s response to fear and the use of MDMA has found that combining this drug with recall therapy and fear extinction learning substantially decreased the fear felt by individuals involved in the study. This comes after...